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Abstract
Background—In clinical trials, lubiprostone reduced the severity of abdominal pain.
Aims—The primary aim was to determine whether lubiprostone raises the threshold for
abdominal pain induced by intraluminal balloon distention. A secondary aim was to determine
whether changes in pain sensitivity influence clinical pain independently of changes in transit
time.
Methods—Sixty-two patients with irritable bowel syndrome with constipation (IBS-C)
participated in an 8-week crossover study. All subjects completed a 14-day baseline ending with a
barostat test of pain and urge sensory thresholds. Half, randomly selected, then received 48 ug/day
of lubiprostone for 14 days ending with a pain sensitivity test and a Sitzmark test of transit time.
This was followed by a 14-day washout and then a crossover to 14 days of placebo with tests of
pain sensitivity and transit time. The other half of the subjects received placebo before
lubiprostone. All kept symptom diaries.
Results—Stools were significantly softer when taking lubiprostone compared to placebo (Bristol
Stool scores 4.20 vs. 3.44, p<0.001). However, thresholds for pain (17.36 vs. 17.83 mmHg,
lubiprostone vs. placebo) and urgency to defecate (14.14 vs. 14.53 mmHg) were not affected by
lubiprostone. Transit time was not significantly different between lubiprostone and placebo (51.27
vs. 51.81 hours), and neither pain sensitivity nor transit time was a significant predictor of clinical
pain.
Conclusions—Lubiprostone has no effect on visceral sensory thresholds. The reductions in
clinical pain that occur while taking lubiprostone appear to be secondary to changes in stool
consistency.
Introduction
Lubiprostone is a chloride channel agonist approved for the treatment of chronic
constipation and irritable bowel syndrome with constipation (IBS-C). Its primary
mechanism of action is secretion of water into the lumen of the small and large intestine1, 2
leading to acceleration of transit, changes in stool consistency, and relief of subjective
symptoms of constipation. However, in clinical trials of patients with IBS-C, it also
decreases abdominal pain and discomfort3, 4 and is effective for the relief of overall
symptoms of IBS4. It is unknown whether these reductions in clinical pain occur secondary
to the effects of the drug on colonic transit or whether they are mediated by a direct effect of
lubiprostone on pain thresholds.
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Sweetser and colleagues5 previously tested the effects of lubiprostone on pain sensitivity in
60 healthy volunteers. A barostat was used to assess the threshold for first sensation and
pain following three daily doses of either 24 µg lubiprostone or placebo. The intensity of
pain produced by standard distention pressures was also tested. There were no significant
differences in either the sensory thresholds or the pain intensity ratings. However, in women
there was a trend favoring higher pain thresholds while taking lubiprostone.
The goal of this study was to reassess the effects of lubiprostone on pain thresholds in
patients with IBS-C using a larger dose and longer exposure (48 µg per day for 14 days). We
also employed a within-subject crossover design to minimize the impact of individual
differences in pain sensitivity. Specific hypotheses were: (1) Pain thresholds will be higher
(i.e., pain sensitivity will be reduced) at the end of two weeks treatment with lubiprostone 48
µg/day compared to two weeks treatment with placebo. (2) Pain thresholds while taking
lubiprostone will remain significantly higher than while taking placebo after adjusting for
differences in transit time. (3) Regression analysis will show that pain threshold and transit




This was a double-blind, randomized cross-over trial, as outlined in Figure 1. A cross-over
design was selected because it requires fewer subjects due to the fact that within-subject
variability is less than between-subject variability, and our prior work suggested good
reproducibility of pain thresholds over an interval of 3 months6. Following enrollment and a
two-week symptom monitoring baseline, subjects were randomly assigned to one of two test
treatment arms, both of which consisted of the same interventions but in a counter-balanced
order. One group received 2 weeks of lubiprostone therapy (48 µg per day) followed by a 2-
week washout period, and then took placebo capsules for 2 weeks. The other group started
with 2 weeks of placebo capsules followed by 2 weeks of washout, and ended with 2 weeks
of lubiprostone therapy (48 ug per day). Two weeks was selected as the duration of the
washout period because the reported elimination half-life of lubiprostone and its major
metabolite is 1.4 hours or less7. After a 24-µg radiolabeled dose of lubiprostone, 60% of the
radioactivity is recovered in the urine within 24 hours and another 30% is recovered in the
feces within 168 hours. The dose of 48 µg per day was selected for testing instead of the
lower 8 µg per day recommended for the treatment of IBS because 48 ug was shown in a
Phase II study to be more effective than lower doses for relief of abdominal pain8. Clinical
symptoms were assessed throughout the study with daily symptom ratings, and symptoms
were also measured with the IBS Severity Scale (IBS-SS)9 at the end of the baseline period
and at the end of each of the two intervention periods. Gut transit time and pain sensitivity
were assessed at the end of each intervention period. Both subjects and study staff were
blinded to the assignment of subjects and the nature of the intervention delivered.
Lubiprostone and placebo were provided by the manufacturer in identical capsules and
dispensed by the University of North Carolina investigational pharmacy.
Sample size
This study was powered to detect a difference in pain threshold only. An a priori sample size
calculation indicated that a minimum of 62 IBS patients would be needed to detect a
clinically meaningful treatment difference of 6 mmHg in the pain threshold between two test
conditions in a cross-over study at an alpha level of 0.05 and power of 80%. The effect size
of 6 mmHg was defined as a clinically meaningful difference because this is half the
difference in average pain thresholds observed between 129 IBS patients and 30 healthy
Whitehead et al. Page 2













controls in a previous study from our laboratory10. Estimates of within subject variability
were taken from the placebo arm of a treatment study we previously reported for which the
difference in pain threshold over a 3-month period was 1.47 mmHg and the standard
deviation of the difference was 8.21 mmHg6.
Recruitment Method and Inclusion/Exclusion criteria
Advertisements in the form of posted signs in clinics or mass emails to the students and staff
of the university invited people with a physician diagnosis of IBS to contact the study staff
for screening. The number screened was not recorded. Inclusion criteria were (1) physician
diagnosis of IBS, (2) meeting Rome III criteria for IBS-C, and (3) age at least 18 years.
Exclusion criteria were: (1) use of laxatives or prokinetic medications within two weeks
prior to the study or during the study; (2) use of IBS-specific compounds, opiates,
anticholinergics, or any drug likely to cause constipation as a side-effect; (3) use of
analgesics for 48 hours prior to the study; (4) hypothyroidism; (5) history of bowel resection
except appendectomy or cholecystectomy; (6) psychotic disorder, major depression,
substance abuse (other than tobacco), or other psychiatric condition likely to interfere with
study participation; (7) renal disease; (8) inflammatory or ischemic disease of the rectum,
and (9) evidence that the subject was an unreliable research participant. (10) Because the
study involved radiographs, women currently pregnant or planning pregnancy, individuals
working with radiation and those who had participated in research involving radiation within
the past year were also excluded.
Individuals meeting inclusion criteria were asked to read and sign and informed consent
statement describing the study and were randomized to one of two drug-placebo sequences
by opening the next in a series of sealed envelopes prepared by the investigational
pharmacy. The investigational pharmacy randomized subjects in blocks of size 6 and 4.
Seventy-one patients were enrolled in the study over a 26-month period, and 62 completed
the trial.
Study Measures
Barostat testing—The barostat test was conducted with a Distender II computer-
controlled pump manufactured by G&J Electronics in Willowdale, Ontario, Canada. The
device is able to inflate and deflate a thin-walled plastic bag in the rectum via a 0.5 cm
diameter polyethylene catheter at pre-specified rates up to 38 ml/sec and to maintain
constant bag pressure by adding or subtracting air from the bag.
The testing followed a protocol that we have used in multiple previous studies. Patients were
asked to prepare for the test by refraining from eating and by not drinking anything other
than water for at least 4 hours prior to testing, and by taking a Fleets enema approximately 2
hours before the test. Subjects were tested in a left lateral position with the barostat bag
placed with its lower margin 5 cm above the anal verge.
The individual operating pressure (IOP), i.e., the minimum pressure required to overcome
passive resistance to bag inflation (mostly attributable to the weight of overlying adipose
tissue) was determined by adding 30 ml of air to the bag, waiting for 3 minutes, and then
measuring the pressure in the bag. This IOP value was used as a correction factor for the
subsequent pain perception tests; it was subtracted from pressures measured during the pain
threshold test to arrive at the “true” trans-mural pressure gradient.
Visceral sensitivity was measured in two ways: by the ascending method of limits (AML)
and by sensory decision theory (SDT). For the AML pain and urge threshold assessment, the
bag in the rectum was inflated with a series of 30 sec distentions separated by 30 sec rest
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periods at zero pressure. Each successive distention was more intense than the last by 2
mmHg, and the patient was asked to rate both pain and urge intensity at the end of each
distention on a six-point intensity rating scale (0–5). The lowest pressure assigned a pain
rating of 3 (“moderate pain”) by the subject defined the AML pain threshold, and the lowest
pressure assigned an urge rating of 3 was used to define the AML urge threshold.
Sensory decision testing immediately followed the AML threshold assessment. It
incorporates classic SDT methodology adapted for colonic and rectal testing and was
developed in our laboratory over a series of studies11, 12. The subjects were presented with a
series of 16 30-sec distention trials separated by 30-sec rest periods at zero pressure. Half of
these trials were at a pressure equivalent to the IOP plus 14 mmHg and the other half at IOP
plus 20 mmHg. Subjects were not informed which pressure intensity was used at each
distention trial. At the end of each distention, subjects were asked to rate the distention with
the same 0–5 rating scale used previously in the AML procedure. From the rating results,
perceptual sensitivity was calculated as an index of ability to accurately discriminate
between the two different intensities of distention (abbreviated P(A)), and a response
criterion was calculated (abbreviated B) as the median intensity rating made by the subject
to all 16 of the stimuli pooled together (i.e., independent of stimulus intensity).
Clinical symptom assessment—Clinical symptoms were assessed in two ways: Via
daily symptom recordings (diary) and the retrospective IBS Severity Scale (IBS-SS)9. In the
symptom diary which subjects completed every night, subjects provided global ratings of the
intensity of their abdominal pain for the past 24 hours, abdominal distention, dissatisfaction
with bowel movements, and interference of bowel symptoms with daily activities. They also
rated the consistency of each bowel movement with guidance from the validated 7-point
Bristol Stool Scale pictures and associated written descriptors13. These ratings were made
by logging onto a password-protected internet site or by telephoning and leaving the data on
the study nurse’s answering machine. To ensure timely completion of the diary, subjects
who failed to report symptoms were telephoned the following day to obtain their symptom
ratings for the previous day. The IBS-SS was completed at the end of the baseline period
and each treatment period. It includes questions about the same symptoms as the first four
questions on the diary (because the diary was designed as an adaptation of the IBS-SS for
daily symptom monitoring) – i.e., pain intensity, distention intensity, bowel habit
dissatisfaction and impact on daily activities, plus an additional question on the number of
days in the past 10 that the subject experienced abdominal pain or discomfort. These five
ratings are totaled to obtain an overall IBS severity score with a maximum severity score of
500. The IBS-SS has been found to discriminate IBS patients from controls and to separate
IBS patients independently categorized by clinicians as mild, moderate, and severe at a high
level of significance9. The scale has also been shown to be responsive to treatment in
multiple treatment studies in IBS14–16.
Sitzmark test of whole gut transit time—The subjects were given 5 capsules
containing 24 circular radio-opaque markers in each and were instructed to take one capsule
at breakfast each morning for 5 days (adapted from Abrahamsson and Antov17). On the
sixth day, subjects reported to the hospital radiology department for an abdominal
radiograph. By counting the markers, whole gut transit time could be estimated in hours. We
report the total number of Sitzmarks remaining in the abdomen on the sixth day as a
measure of whole gut transit time and the number of Sitzmarks in the left hemicolon (i.e., all
Sitzmark lying on the right of the midline) as a measure of transit through the ascending
colon. All female subjects who were pre-menopausal received a urine pregnancy test before
each radiograph to confirm that they were not pregnant.
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Procedures: In the course of their participation in the study, subjects completed a total of 7
outpatient visits to the General Clinical Research Center. Study procedures on each visit
were as summarized below:
Visit 1: A screening interview was conducted, an informed consent completed, and the
subject was given instruction in using the study diary and in taking a Fleets enema.
Visit 2 (2 weeks after Visit 1): The subject’s study diary was reviewed to verify that
symptoms met eligibility criteria, the IBS-SS questionnaire was administered, barostat
test 1 conducted, the study capsules for the first treatment period issued, and
instructions given for taking Sitzmarks capsules for the transit time study.
Visit 3 (2 weeks after Visit 2): An abdominal radiograph was taken for the transit time
study.
Visit 4 – end of Treatment Period 1 (1–3 days after Visit 3): Unused intervention
capsules were collected from the subject and counted, the IBS-SS questionnaire and
treatment assignment perception question was administered and barostat test 2 was
performed.
Visit 5 (2 weeks after visit 4): The IBS-SS questionnaire was administered, the
intervention capsules for Treatment Period 2 were issued, and instructions were given
for taking Sitzmarks for the transit study.
Visit 6: An abdominal radiograph was taken for the transit time study.
Visit 7 – end of Treatment Period 2 (1–3 days after Visit 6): Unused medication
capsules were collected and counted, the IBS-SS questionnaire and perceived treatment
arm questionnaire were administered, and a barostat test 3 was completed.
Subjects were paid $500 for completing the study. The study was reviewed and approved by
the Biomedical Institutional Review Board at the University of North Carolina at Chapel
Hill before enrollment was initiated. The trial was registered with ClinicalTrials.gov as NCT
01166789.
Data analysis
By design, a random half of the subjects received lubiprostone followed by placebo, and the
other half of subject received the placebo before lubiprostone. General linear models for
repeated measures (SPSS version 19.0) was used to analyze the data. Treatment intervals 1
and 2 constituted the repeated measure and order was a between-subjects factor. For
dependent measures recorded during baseline (pain thresholds recorded by barostat, urge
thresholds recorded by barostat, and diary measures of stool consistency, abdominal pain,
bloating, dissatisfaction with bowel habits, and interference with life) the baseline value was
entered as a covariate. Transit measures were not assessed during baseline to minimize
radiation exposure, so no covariate was available for this measure. All dependent variables
were assumed to be normally distributed on continuous, equal interval scales. In these GLM
models, support for the hypothesis of a drug effect would be reflected in a significant
treatment period by order effect. Linear regression analysis was used to test the third
hypothesis, namely that pain threshold and transit time both make independent significant
contributions to clinical pain, and this was tested separately for each treatment period. Alpha
was set to 0.05 for all analyses to minimize Type II statistical errors. The data are reported
as means and 95% confidence intervals (CI).
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Average age of patients was 41.95+13.56 (mean+S.D.) years, and 85.5% were women. Race
composition was 66.1% white, 19.0% black, and 3.2% Asian. Average IBS-SS severity
score at the end of baseline (computed from the questionnaire) was 295.65 [CI 274.08,
317.21] with 8.1% of subjects scoring in the mild range (score <175), 46.7% of patients
scoring in the moderate range (i.e., 175–300)9 and the remaining 45.2% in the severe range
(i.e., >300).
Adherence with taking study drug
Patients were instructed to take two capsules daily. There was no difference in the average
number of capsules taken during Lubiprostone versus the average number taken during
placebo administration (1.96 per day [CI 1.81, 2.03] vs. 1.98 per day [CI 1.89, 2.06];
t(54)=0.351, p=0.727), and adherence with medication taking was excellent overall.
Test for carry-over effects
To test for carry-over effects after medication use, the IBS-SS questionnaire was
administered at the end of the washout period. There was no significant carry-over effect,
although there was a tendency for patients receiving active drug during Treatment Period 1
to have a lower IBS-SS at the end of washout than subjects receiving placebo in Treatment
Period 1 (245.67 [CI, 212.90, 278.44] vs. 261.67 [228.90, 294.44], p=.492),
Stool consistency and whole gut transit time
Table 1 shows that average Bristol Stool Scale scores computed from the daily diary were
significantly greater (softer stools) when patients were taking active drug compared to
placebo after adjusting for order of administration. Table 1 also shows that the proportion of
days with hard/lumpy stools or no stools was significantly lower on active drug compared to
placebo after adjusting for order of administration. However, neither whole gut transit time
nor transit through the right hemicolon was significantly different on drug compared to
placebo. The correlation between transit time as measured by the Sitzmark test and average
stool consistency measured by the Bristol Stool Scale was rho = −0.346 (p=0.007) for the
placebo condition and rho = −0.113 (p=0.366) for the lubiprostone condition.
Abdominal pain and other IBS symptoms
There were no differences between lubiprostone and placebo for diary ratings of abdominal
pain, distention, dissatisfaction with bowel habits, or interference with life activities (Table
1). Similarly, there were no differences between drug and placebo on the IBS-SS
questionnaires completed at the end of each treatment period.
Sensory thresholds
Pain thresholds could not be calculated for 20 of 62 patients by the ascending method of
limits because they reached intolerable levels of urgency to defecate before reporting
moderate levels of pain in one or more periods, and urge thresholds could not be calculated
for 14 patients because they reached intolerable levels of pain before reporting a moderate
urge sensation in one or more periods. Missing data were similar for drug and placebo (11
vs. 14 missing pain values and 6 vs. 5 missing urge thresholds respectively) which indicates
that missing data was unrelated to drug administration; consequently, these subjects were
excluded from analysis of pain and urge sensitivity. Pain and urge thresholds for the
evaluable patients are shown in figures 2 and 3. A significant drug effect after adjustment
for order of testing would be indicated by a significant interaction between drug treatment
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and period, but both interaction terms were non-significant (F<1.0, p>.90 in both cases).
Figures 2 and 3 show that sensory thresholds increase with successive barostat tests, but the
magnitude of increases in pain and urge thresholds from the first to the third barostat test
were less than the 6 mmHg which we defined a priori as a clinically insignificant change.
Moreover, when the data were pooled across treatment periods, There were no significant
differences between lubiprostone and placebo either for pain thresholds or urge thresholds
(t<1.0 in both cases).
The sensory decision theory indices for visceral sensitivity are shown in Table 2. Neither the
neurosensory sensitivity index, P(A), nor the response criterion, B, showed a significant
difference between active drug and placebo.
By limiting the analysis to the first intervention period, we could test for the effects of
lubiprostone versus placebo on pain and urge thresholds while adjusting for transit time.
There was no significant difference between lubiprostone and placebo following this
adjustment (F(1,46)=0.329, p=0.569). Regression analyses applied to each intervention
period separately confirmed that none of three variables – drug, whole gut transit time, or
abdominal pain threshold – was a significant predictor of abdominal pain (data not shown).
Discussion
The principal finding of this study is that lubiprostone at a dose of 48 µg per day does not
have a significant impact on the sensory thresholds for pain or urgency to defecate. Sensory
decision theory, which separates psychological and neurosensory influences on pain
reporting, likewise failed to show a difference between lubiprostone and placebo. These data
confirm the report by Sweetser and colleagues5 who found no significant effect of
lubiprostone on pain sensitivity in 60 healthy controls. Because the Sweetser study was
conducted in healthy subjects and tested pain sensitivity after only 3 days of taking 24 µug
of lubiprostone per day, it was possible that an effect might have been missed. However, in
our study no difference in sensory thresholds was seen although 92% of subjects had
moderate to severe IBS symptoms, they were treated for 14 days before testing, and a higher
daily dose of 48 µg per day was administered. Thus, it is unlikely that lubiprostone has an
effect on visceral sensory thresholds.
A second aim of this study was to determine whether the effects of lubiprostone on clinical
pain in IBS patients is mediated by changes in transit time or by changes in pain sensitivity.
However, no significant reductions in the average intensity of abdominal pain were found
when comparing lubiprostone to placebo. This was not a consequence of poor adherence or
the absence of a clinical response to drug: lubiprostone had the expected effect of
significantly changing stool consistency towards softer or looser stools and compliance with
medication use was very good.
We did not observe a significant difference in transit time as measured by the Sitzmark
study between lubiprostone and placebo intervals despite the significant difference in stool
consistency ratings. This was unexpected since a previous study showed a significant
acceleration of colonic transit time by lubiprostone18. This earlier study used a different
method for measuring colonic transit, namely measurement of the distribution of a
radioisotope 24 and again 48 hours after ingestion, suggesting the possibility that the
Sitzmark transit test used in our study (modified from Abrahamsson and Antov17) may have
been insensitive. However, we believe this explanation is unlikely because, during the
placebo treatment period, we were able to replicate the significant negative correlation
between transit time and stool consistency that was previously reported by Lewis and
colleagues using a Sitzmark technique13. It was only during the lubiprostone treatment
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period that transit time showed a non-significant relationship to stool consistency. We
speculate that this occurred because the secretion of water into the bowel that is induced by
lubiprostone has a direct effect on stool consistency and only an indirect effect on transit
time.
A possible limitation of this study is that it may have been underpowered to detect a
significant effect of lubiprostone on pain thresholds. Prior to the study we calculated that 62
subjects would be needed to have 80% power to detect a clinically meaningful difference of
6 mmHg in pain thresholds between lubiprostone and placebo, and we enrolled 62 patients.
However, missing data, which occurred because some patients requested early
discontinuation of the sequence of distentions because of an intolerable urge to defecate, left
us with an analysis sample of 42 patients for pain thresholds. Missing data appeared to be
random with respect to drug vs. placebo, however, so we believe this is unlikely to have
obscured a true effect of lubiprostone on pain thresholds. Moreover, we did not observe an
effect of lubiprostone on the urge threshold.
A potential problem with a cross-over design such as the one used here is that treatment
effects may carry over from one treatment period to another. To minimize this we
introduced a washout period between treatment periods that is known to be much greater
than the elimination half-life of lubiprostone in the body7. We also tested for carry over
effects by administering the IBS-SS questionnaire at the end of washout as well as at the end
of each treatment period. This failed to show a significant difference in symptom severity at
the end of washout between patients treated with lubiprostone vs. those treated with placebo
in the preceding treatment period. In the only study19 in the literature to systematically
evaluate the relapse rate for constipation following 4 weeks of lubiprostone 24 µg twice
daily, 44% of patients with chronic constipation who were responders to lubiprostone
relapsed by the third week after being switched to placebo. However, the average severity of
constipation had not returned to baseline by this time.
Another limitation of the study is that we failed to observe a significant effect of
lubiprostone on diary ratings of abdominal pain and other IBS symptoms as others have
shown. This may be a consequence of not powering the study to detect these differences.
In conclusion, our data and those of Sweetser et al5 suggest that the reductions in clinical
pain reported in trials of lubiprostone3, 4 are unlikely to be due to changes in pain sensitivity.
Based on our data, we speculate that reductions in clinical pain may be due to changes in
stool consistency. This shift towards softer stools may reduce the frequency with which the
lumen of the bowel is distended sufficiently to induce pain.
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Thresholds for moderate pain (rating of 3 on a 0–5 scale), determined by the ascending
method of limits. Light gray, baseline or placebo; black, lubiprostone 48 ug/day.
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Threshold for sustained urge to defecate, determinded by the ascending method of limits.
Light gray, baseline or placebo condition; black, lubiprostone 48 ug/day.
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Table 2
Baseline Placebo Lubiprostone
P(A) for pain 0.58 [CI, 0.55, 0.61] 0.60 [CI, 0.57, 0.63] 0.59 [CI, 0.56, 0.63]
P(A) for urge 0.67 [CI, 0.63, 0.71] 0.68 [CI, 0.65, 0.71] 0.68 [CI, 0.65, 0.72]
B for pain 3.41 [CI, 3.14, 3.67] 3.55 [CI, 3.25, 3.86] 3.47 [CI, 3.17, 3.77]
B for urge 2.44 [CI, 2.18, 2.69] 2.68 [CI, 2.40, 2.95] 2.66 [CI, 2.41, 2.90]
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